Your session is about to expire
← Back to Search
Other
Study of AC0058TA in Patients With Systemic Lupus Erythematosus (SLE)
Phase 1
Waitlist Available
Led By Roy Fleischmann, MD MACR
Research Sponsored by ACEA Therapeutics, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Summary
This is a Phase 1b, double blind, randomized, placebo-controlled study of the safety and tolerability, pharmacokinetics and pharmacodynamics of AC0058TA in patients with systemic lupus erythematosus (SLE).
Eligible Conditions
- Lupus
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
Treatment Details
Trial Design
2Treatment groups
Experimental Treatment
Placebo Group
Group I: AC0058TAExperimental Treatment1 Intervention
AC0058TA will be administered in 25 mg capsules orally at the following doses: 50 mg QD, 100 mg QD, 200 mg QD and 100 mg BID
Group II: Placebo AC0058TAPlacebo Group1 Intervention
Placebo AC0058TA will be administered orally at the equivalent dose of investigational product
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
AC0058TA
2016
Completed Phase 1
~60
Find a Location
Who is running the clinical trial?
ACEA Therapeutics, Inc.Lead Sponsor
2 Previous Clinical Trials
84 Total Patients Enrolled
Hangzhou ACEA Pharmaceutical Research Co., Ltd.Industry Sponsor
8 Previous Clinical Trials
1,294 Total Patients Enrolled
Roy Fleischmann, MD MACRPrincipal InvestigatorMetroplex Clinical Research Center